A Decade of Change: Recent Developments in Pharmacotherapy of Hereditary Angioedema (HAE)

Clinical Reviews in Allergy and Immunology

Volumn 51, Issue 2, 2016, Pages 183-192

  Bork, Konrad ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

C1 inhibitor; C1 INH deficiency; Hereditary angioedema; Prophylaxis; Treatment for acute attacks

Indexed keywords

AMINOCAPROIC ACID; ANDROGEN; ANTIFIBRINOLYTIC AGENT; AVORALSTAT; BRADYKININ; BRADYKININ B2 RECEPTOR ANTAGONIST; COMPLEMENT COMPONENT C1S INHIBITOR; DANAZOL; ECALLANTIDE; GESTAGEN; ICATIBANT; KALLIKREIN; KALLIKREIN INHIBITOR; LANADELUMAB; NEUTRALIZING ANTIBODY; STANOZOLOL; TRANEXAMIC ACID; BRADYKININ ANTAGONIST; KININ;

ANGIONEUROTIC EDEMA; CAUSAL ATTRIBUTION; CLINICAL EFFECTIVENESS; COMPLEMENT DEFICIENCY; COST BENEFIT ANALYSIS; DISEASE ASSOCIATION; DRUG COST; DRUG EFFICACY; DRUG TARGETING; HUMAN; IMMUNOPROPHYLAXIS; PROTEIN SECRETION; REVIEW; TREATMENT OUTCOME; TREATMENT PLANNING; ANGIOEDEMAS, HEREDITARY; ANTAGONISTS AND INHIBITORS; DISEASE COURSE; METABOLISM; PREMEDICATION;

ANGIOEDEMAS, HEREDITARY; ANTIFIBRINOLYTIC AGENTS; BRADYKININ RECEPTOR ANTAGONISTS; COMPLEMENT C1 INHIBITOR PROTEIN; DISEASE PROGRESSION; HUMANS; KALLIKREINS; KININS; PREMEDICATION;

EID: 84969790498     PISSN: 10800549     EISSN: 15590267     Source Type: Journal    
DOI: 10.1007/s12016-016-8544-9     Document Type: Review

References (47)

1. Bork K, Hardt J, Witzke G (2012) Fatal laryngeal attacks and mortality in hereditary angioedema due to C1-INH deficiency. J Allergy Clin Immunol 130:692–697
2. Bork K, Maurer M, Bas M et al. (2011) German guidelines for hereditary angioedema due to C1-INH deficiency. Mainz: German Society for Angioedema Research. Available in English at www.angioedema.de/englisch/infos.htm. Accessed 21 Dec 2015
3. Cicardi M, Bork K, Caballero T, Craig T, Li HH, Longhurst H, Reshef A, Zuraw B (2012) Evidence-based recommendations for the therapeutic management of angioedema owing to hereditary C1 inhibitor deficiency: consensus report of an International Working Group. Allergy 67:147–157
4. Craig T, Aygoren-Pursun E, Bork K, Bowen T, Boysen H, Farkas H, Grumach A, Katelaris CH, Lockey R, Longhurst H et al (2012) WAO guideline for the management of hereditary angioedema. World Allergy Organ J 5:182–199
5. Gandhi PK, Gentry WM, Bottorff MB (2012) Thrombotic events associated with C1 esterase inhibitor products in patients with hereditary angioedema: investigation from the United States Food and Drug Administration adverse event reporting system database. Pharmacotherapy 32:902–909
6. Bork K, Bygum A, Hardt J (2008) Benefits and risks of danazol in hereditary angioedema: a long-term survey of 118 patients. Ann Allergy Asthma Immunol 100:153–161
7. Craig TJ, Levy RJ, Wasserman RL, Bewtra AK, Hurewitz D, Obtulowicz K, Reshef A, Ritchie B, Moldovan D, Shirov T et al (2009) Efficacy of human C1 esterase inhibitor concentrate compared with placebo in acute hereditary angioedema attacks. J Allergy Clin Immunol 124:801–808
8. Bork K, Meng G, Staubach P, Hardt J (2005) Treatment with C1 inhibitor concentrate in abdominal pain attacks of patients with hereditary angioedema. Transfusion 45:1774–1784
9. Farkas H, Jakab L, Temesszentandrasi G, Visy B, Harmat G, Fust G, Szeplaki G, Fekete B, Karadi I, Varga L (2007) Hereditary angioedema: a decade of human C1-inhibitor concentrate therapy. J Allergy Clin Immunol 120:941–947
10. Bork K, Staubach P, Hardt J (2008) Treatment of skin swellings with C1-inhibitor concentrate in patients with hereditary angio-oedema. Allergy 63:751–757
11. Rizk C, Karsh J, Santucci S, Yang W (2013) Self-administration of intravenous C1 esterase inhibitor in hereditary angioedema. CMAJ 185:791–792
12. Bork K (2014) Pasteurized and nanofiltered, plasma-derived C1 esterase inhibitor concentrate for the treatment of hereditary angioedema. Immunotherapy 6:533–551
13. Bork K, Hardt J (2009) Hereditary angioedema: increased number of attacks after frequent treatments with C1 inhibitor concentrate. Am J Med 122:780–783
14. Kalfus I, Frank M (2010) C1 inhibitor therapy and hereditary angioedema. Am J Med 123:e15, Author reply e17
15. Bork K, Hardt J (2011) Hereditary angioedema: long-term treatment with one or more injections of C1 inhibitor concentrate per week. Int Arch Allergy Immunol 154:81–88
16. Cinryze: European Public Assessment Report. London, UK (2011) European Medicines Authority. Available at: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/001207/human_med_001448.jsp&mid=WC0b01ac058001d124 Accessed 21 Dec 2015
17. Lumry W, Manning ME, Hurewitz DS, Davis-Lorton M, Fitts D, Kalfus IN, Uknis ME (2013) Nanofiltered C1-esterase inhibitor for the acute management and prevention of hereditary angioedema attacks due to C1-inhibitor deficiency in children. J Pediatr 162(1017–1022):e1011–e1012
18. Tourangeau LM, Castaldo AJ, Davis DK, Koziol J, Christiansen SC, Zuraw BL (2012) Safety and efficacy of physician-supervised self-managed c1 inhibitor replacement therapy. Int Arch Allergy Immunol 157:417–424
19. Hock FJ, Wirth K, Albus U, Linz W, Gerhards HJ, Wiemer G, Henke S, Breipohl G, Konig W, Knolle J et al (1991) Hoe 140 a new potent and long acting bradykinin-antagonist: in vitro studies. Br J Pharmacol 102:769–773
20. Wirth K, Hock FJ, Albus U, Linz W, Alpermann HG, Anagnostopoulos H, Henk S, Breipohl G, Konig W, Knolle J et al (1991) Hoe 140 a new potent and long acting bradykinin-antagonist: in vivo studies. Br J Pharmacol 102:774–777
21. Bork K, Yasothan U, Kirkpatrick P (2008) Icatibant. Nat Rev Drug Discov 7:801–802
22. Bork K, Frank J, Grundt B, Schlattmann P, Nussberger J, Kreuz W (2007) Treatment of acute edema attacks in hereditary angioedema with a bradykinin receptor-2 antagonist (Icatibant). J Allergy Clin Immunol 119:1497–1503
23. Cicardi M, Banerji A, Bracho F, Malbran A, Rosenkranz B, Riedl M, Bork K, Lumry W, Aberer W, Bier H et al (2010) Icatibant, a new bradykinin-receptor antagonist, in hereditary angioedema. N Engl J Med 363:532–541
24. Lumry WR, Li HH, Levy RJ, Potter PC, Farkas H, Moldovan D, Riedl M, Li H, Craig T, Bloom BJ et al (2011) Randomized placebo-controlled trial of the bradykinin B receptor antagonist icatibant for the treatment of acute attacks of hereditary angioedema: the FAST-3 trial. Ann Allergy Asthma Immunol 107:529–537
25. Maurer M, Aberer W, Bouillet L, Caballero T, Fabien V, Kanny G, Kaplan A, Longhurst H, Zanichelli A (2013) Hereditary angioedema attacks resolve faster and are shorter after early icatibant treatment. PLoS One 8:e53773
26. Aberer W, Maurer M, Reshef A, Longhurst H, Kivity S, Bygum A, Caballero T, Bloom B, Nair N, Malbran A (2014) Open-label, multicenter study of self-administered icatibant for attacks of hereditary angioedema. Allergy 69:305–314
27. Cicardi M, Levy RJ, McNeil DL, Li HH, Sheffer AL, Campion M, Horn PT, Pullman WE (2010) Ecallantide for the treatment of acute attacks in hereditary angioedema. N Engl J Med 363:523–531
28. Levy RJ, Lumry WR, McNeil DL, Li HH, Campion M, Horn PT, Pullman WE (2010) EDEMA4: a phase 3, double-blind study of subcutaneous ecallantide treatment for acute attacks of hereditary angioedema. Ann Allergy Asthma Immunol 104:523–529
29. Sheffer AL, MacGinnitie AJ, Campion M, Stolz LE, Pullman WE (2013) Outcomes after ecallantide treatment of laryngeal hereditary angioedema attacks. Ann Allergy Asthma Immunol 110:184–188.e182
30. MacGinnitie AJ, Davis-Lorton M, Stolz LE, Tachdjian R (2013) Use of ecallantide in pediatric hereditary angioedema. Pediatrics 132:e490–e497
31. Li HH, Campion M, Craig TJ, Soteres DF, Riedl M, Lumry WR, MacGinnitie AJ, Shea EP, Bernstein JA (2013) Analysis of hereditary angioedema attacks requiring a second dose of ecallantide. Ann Allergy Asthma Immunol 110:168–172
32. Zuraw B, Cicardi M, Levy RJ, Nuijens JH, Relan A, Visscher S, Haase G, Kaufman L, Hack CE (2010) Recombinant human C1-inhibitor for the treatment of acute angioedema attacks in patients with hereditary angioedema. J Allergy Clin Immunol 126:821–827.e814
33. Riedl MA, Levy RJ, Suez D, Lockey RF, Baker JW, Relan A, Zuraw BL (2013) Efficacy and safety of recombinant C1 inhibitor for the treatment of hereditary angioedema attacks: a North American open-label study. Ann Allergy Asthma Immunol 110:295–299
34. Riedl MA, Bernstein JA, Li H, Reshef A, Lumry W, Moldovan D, Farkas H, Levy R, Baker J, Hardiman Y et al (2014) Recombinant human C1-esterase inhibitor relieves symptoms of hereditary angioedema attacks: phase 3, randomized, placebo-controlled trial. Ann Allergy Asthma Immunol 112:163–169.
35. Sheffer AL, Austen KF, Rosen FS (1972) Tranexamic acid therapy in hereditary angioneurotic edema. N Engl J Med 287:452–454
36. Fust G, Farkas H, Csuka D, Varga L, Bork K (2011) Long-term efficacy of danazol treatment in hereditary angioedema. Eur J Clin Investig 41:256–262
37. Zuraw BL, Busse PJ, White M, Jacobs J, Lumry W, Baker J, Craig T, Grant JA, Hurewitz D, Bielory L et al (2010) Nanofiltered C1 inhibitor concentrate for treatment of hereditary angioedema. N Engl J Med 363:513–522
38. Zuraw BL, Kalfus I (2012) Safety and efficacy of prophylactic nanofiltered C1-inhibitor in hereditary angioedema. Am J Med 125:931–937
39. Bernstein JA, Manning ME, Li H, White MV, Baker J, Lumry WR, Davis-Lorton MA, Jacobson KW, Gower RG, Broom C et al (2014) Escalating doses of C1 esterase inhibitor (CINRYZE) for prophylaxis in patients with hereditary angioedema. J Allergy Clin Immunol Pract 2:77–84.
40. Bork K, Witzke G (1989) Long-term prophylaxis with C1-inhibitor (C1 INH) concentrate in patients with recurrent angioedema caused by hereditary and acquired C1-inhibitor deficiency. J Allergy Clin Immunol 83:677–682
41. Martinez-Saguer I, Heller C, Fischer D, Ettingshausen CE, W. K (1999) Prophylactic treatment with pasteurised C1 inhibitor in hereditary angioedema (HAE)—a prospective 32 months follow up. Blood 94(10), Sup 1, Abstract # 1032:2339
42. Tallroth GA (2011) Long-term prophylaxis of hereditary angioedema with a pasteurized C1 inhibitor concentrate. Int Arch Allergy Immunol 154:356–359
43. Reshef A, Moldovan D, Obtulowicz K, Leibovich I, Mihaly E, Visscher S, Relan A (2013) Recombinant human C1 inhibitor for the prophylaxis of hereditary angioedema attacks: a pilot study. Allergy 68:118–124
44. Martinez-Saguer I, Cicardi M, Suffritti C, Rusicke E, Aygoren-Pursun E, Stoll H, Rossmanith T, Feussner A, Kalina U, Kreuz W (2014) Pharmacokinetics of plasma-derived C1-esterase inhibitor after subcutaneous versus intravenous administration in subjects with mild or moderate hereditary angioedema: the PASSION study. Transfusion 54:1552–1561
45. Zuraw BL, Cicardi M, Longhurst HJ, Bernstein JA, Li HH, Magerl M, Martinez-Saguer I, Rehman SM, Staubach P, Feuersenger H et al (2015) Phase II study results of a replacement therapy for hereditary angioedema with subcutaneous C1-inhibitor concentrate. Allergy 70:1319–1328
46. Spath PJ, Wuthrich B, Butler R (1984) Quantification of C1-inhibitor functional activities by immunodiffusion assay in plasma of patients with hereditary angioedema—evidence of a functionally critical level of C1-inhibitor concentration. Complement 1:147–159
47. Bhattacharjee G, Revenko AS, Crosby JR, May C, Gao D, Zhao C, Monia BP, MacLeod AR (2013) Inhibition of vascular permeability by antisense-mediated inhibition of plasma kallikrein and coagulation factor 12. Nucleic Acid Ther 23:175–187